Bicycle Therapeutics plc - BCYC Income before deduction of interest, taxes and amortization

Brandmark of Bicycle Therapeutics PLC (BCYC)

Bicycle Therapeutics (BCYC) success is based on bicyclic peptide data and payments from pharmaceutical partners. The operating profit summary serves as a financial health scanner, where the value 0.00 captures this metric. The company's growth depends on clinical stages rather than economics. Meanwhile, R&D cost optimization is achieved by engaging external research organizations.

BCYC: Bicycle Corp Profit before payment of interest, taxes and amortization 11/23/2025 - 11/12/2026

Bicycle Therapeutics plc - analytical breakdowns and key metrics (BCYC)

- market value and analyst target forecast:
Market Price Bicycle Corp|BCYC - Consensus Target
- issuer market value details:
Market Value Bicycle Therapeutics|BCYC - Total Company Value
- book capitalization information:
Share Book Value Bicycle Therapeutics|BCYC - Company Book Value|Market Value to Book Value Ratio bicycletherapeutics.com|BCYC - Company Total Assets
- debt level and financial liquidity data:
Total Debt to Capital Bicycle Therapeutics|BCYC - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Bicycle Therapeutics PLC|BCYC - Company Aggregate Debts|Debts to Book Capitalization Ratio Bicycle Therapeutics|BCYC - Company Long-Term Debt|Short-Term Debt Bicycle Therapeutics|Intermediate Coverage Ratio bicycletherapeutics.com
- earnings and valuation multiples information:
BCYC - Company Net Income|Future Profit Bicycle Therapeutics|BCYC - Price to Earnings Ratio|Market Cap to Projected Earnings bicycletherapeutics.com|BCYC - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bicycle Therapeutics|BCYC - Operating profit EBITDA|Net earnings per share for the last four quarters Bicycle Therapeutics|BCYC - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months bicycletherapeutics.com|BCYC - Net earnings per share growth this year|Expected net earnings per share growth next year Bicycle Therapeutics
Summary company analytics:Bicycle Corp, BCYC
Original product of bicycletherapeutics.com

Professional capital evaluates Bicycle Therapeutics (BCYC) through the lens of cash flow management efficiency. This indicator captures the actual volume of operating income by excluding non-cash expenses, as reflected in the value of 0.00. An analysis of total EBITDA reveals the biotech's ability to maintain viability without external financing. For a non-cyclical business dependent on clinical phases, negative dynamics here signal high vulnerability to macro shocks. The stability of this metric determines the asset's reliability.

Competitors of Bicycle Therapeutics (BCYC)

Geron Bio (GERN) - Profit before interest, taxes and amortization|NBTX: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization CTMX (cytomx.com)|perspectivetherapeutics.com (CATX) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization GNLX (Genelux)|Profit before payment of interest, taxes and amortization Molecular Partners AG|Profit before payment of interest, taxes and amortization ONCY|Operating profit EBITDA LSTA|Operating profit EBITDA moleculin.com (MBRX)|Galera Therapeutics, Inc. - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization MTEM (Molecular Templates Inc)